Tempus ECG-Low EF vs KardiaAI
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary objective is to screen for potential low left ventricular ejection fraction (LVEF ≤40%) in patients aged 40 or older using standard 12-lead ECGs. This tool is best suited for integration into healthcare facility workflows to aid clinicians in identifying patients at risk of heart failure who may require further cardiac evaluation.
View Tempus ECG-Low EF →Choose KardiaAI if…
Choose KardiaAI if you require a flexible, API-driven solution for analyzing ambulatory ECG rhythms to detect a wide range of cardiac conditions, including atrial fibrillation, bradycardia, and tachycardia. This tool is ideal for integration into mobile apps, web platforms, or other ECG devices for continuous or intermittent rhythm monitoring, offering broad arrhythmia detection capabilities.
View KardiaAI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | KardiaAI |
|---|---|---|
| Pricing | Unknown | Subscription-based for advanced features and services. |
| Deployment | Integrates with current ECG platforms and electronic health records (EHRs). | Mobile app, cloud-based. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
KardiaAITool B (KardiaAI) offers a more direct and interactive user experience through its mobile app and web platforms, catering to both clinicians and patients. Its portability and ease of use for recording ECGs on demand provide broader accessibility. In contrast, Tool A (Tempus ECG-Low EF) operates primarily as background software integrated into facility workflows, lacking a dedicated user interface for direct interaction.
Clinical Value
KardiaAIWhile Tool A (Tempus ECG-Low EF) provides significant value by detecting low LVEF, a critical and often undiagnosed condition, Tool B (KardiaAI) offers a broader suite of 35 cardiac determinations, including life-threatening conditions like acute myocardial infarction and various arrhythmias. Its wider diagnostic scope and proven ability to reduce urgent healthcare utilization give it a slight edge in overall clinical impact.
Pricing & Value
KardiaAITool B (KardiaAI) offers transparent, accessible, and relatively low-cost subscription options for individuals, alongside enterprise solutions. Tool A (Tempus ECG-Low EF) requires direct vendor contact for pricing, making its value proposition less transparent and likely geared towards larger, custom implementations.
Enterprise Readiness
TieBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating strong foundational readiness for enterprise use. Tool A (Tempus ECG-Low EF) explicitly integrates into healthcare facility workflows and EHRs, while Tool B (KardiaAI) offers an enterprise platform with API integration and additional certifications like ISO 27001 and SOC 2 Type 2.
Innovation
KardiaAIWhile Tool A's (Tempus ECG-Low EF) ability to detect low LVEF from a standard ECG is innovative, Tool B's (KardiaAI) recent KAI 12L AI technology, which can detect 35 cardiac determinations including heart attacks using a portable, reduced-leadset 12-lead ECG system, represents a broader and more comprehensive innovation in accessible cardiac diagnostics.
Support & Docs
KardiaAITool B (KardiaAI) provides more extensive and easily accessible support resources, including detailed user manuals in multiple languages, a dedicated FAQ section, and clear contact channels for both general and professional users. While Tool A (Tempus ECG-Low EF) offers support via email and representatives, the breadth and accessibility of documentation appear more robust for KardiaAI.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | KardiaAI |
|---|---|---|
| Name | Tempus ECG-Low EF | KardiaAI |
| Company | Tempus AI | AliveCor |
| Description | Tempus ECG-Low EF is an FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. | KardiaAI by AliveCor is an FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia. |
| Key Features | AI-powered algorithm for ECG analysis; Detects signs of low Left Ventricular Ejection Fraction (LVEF u226440%); Analyzes resting, non-ambulatory 12-lead ECG recordings; Provides a binary output (Low LVEF Detected / Not Detected); Aids in identifying patients 40+ years at risk of heart failure; Trained on a large dataset of over 930,000 ECGs from 170,000+ patients; Intended for use in clinical diagnostic settings at healthcare facilities | AI-powered ECG analysis library; Detection of atrial fibrillation, bradycardia, tachycardia, and normal sinus rhythm; Detection of Sinus Rhythm with Premature Ventricular Contractions (PVCs); Detection of Sinus Rhythm with Wide QRS; Detection of Sinus Rhythm with Supraventricular Ectopy (SVE); ECG noise filtering and noisy ECG detection; API library for integration into other ECG devices and software; Medical-grade accuracy for heart rhythm data |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and KardiaAI.
More Comparisons
More matchups featuring Tempus ECG-Low EF or KardiaAI
Backers
Who funded each tool's parent company.